InvestorsHub Logo
Followers 138
Posts 23702
Boards Moderated 0
Alias Born 04/08/2004

Re: georgejjl post# 192

Tuesday, 10/19/2021 11:40:25 AM

Tuesday, October 19, 2021 11:40:25 AM

Post# of 255
It appears there are very very good results for the Phase 1/2 Trial of AXO-AAV-GM1 Gene Therapy for the Treatment of Infantile- and Juvenile-onset GM1 Gangliosidosis:

Phase 1/2 Trial of AXO-AAV-GM1 Gene Therapy for the Treatment of Infantile- and Juvenile-onset GM1 Gangliosidosis


C Tifft12 P D'Souza12 J M Johnston12 M T Acosta12 E R Nicoli12 C Rothermel12 A Thurm13 A Karunakara4 B Thorp4 P Ross4 J Jameson4 M Sheehan4 T Vaughn4 D Valencia4 E De Boever4 G Corcoran4

1: National Institutes of Health 2: National Human Genome Research Institute 3: National Institute of Mental Health 4: Sio Gene Therapies Inc.

Data is presented from an ongoing open-label, single-arm, dose-ranging Phase 1/2 trial (NCT03952637) of an investigational gene therapy AXO-AAV-GM1 (AAV9-GLB1) for treatment of GM1 gangliosidosis which is a rare, fatal, neurodegenerative lysosomal storage disorder. Subjects are administered AXO-AAV-GM1 intravenously following immune modulation with rituximab, sirolimus and glucocorticoids. Seven subjects have been enrolled in 2 cohorts: low-dose (1.5x1013 vg/kg), n?=?4 late-infantile-onset and n?=?1 juvenile-onset, follow-up 12-months; high-dose (4.5x1013 vg/kg), n?=?2 juvenile-onset, follow-up 6-months. AXO-AAV-GM1 was generally safe and well-tolerated. There were two serious adverse events unrelated to AXO-AAV-GM1. Six subjects had adverse events of AST or ALT elevations (≤5X above baseline) that did not require clinical intervention or have associated clinical sequelae and no adverse events of elevations in GGT or bilirubin were reported. At 6-months, CSF GM1 ganglioside was reduced to published normal levels and serum ß-gal enzyme activity increased above the lower limit of normal reference levels in the high-dose subjects. At 12-months, the CSF GM1 ganglioside remained below baseline levels in all low-dose subjects and serum ß-gal activity remained above baseline levels in two of five subjects. Volumetric MRI data in low-dose subjects showed maintenance of brain volume in four of five subjects at 12-months. There was no clinical evidence of disease progression in four of five low-dose subjects at 12-months or in the high-dose cohort at 6-months post-treatment as assessed by Vineland-3, Upright/Floor Mobility Score, Clinical Global Impression, and neurological examination. Further evaluation of these subjects is ongoing

Good luck and GOD bless,
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.